Vaccines Incorporating Toll-Like Receptor Ligands - Attaching the HA antigen to a TLR can produce a strong immunogenic response and can be produced quickly and easily in E. coli. - BioPharm

ADVERTISEMENT

Vaccines Incorporating Toll-Like Receptor Ligands
Attaching the HA antigen to a TLR can produce a strong immunogenic response and can be produced quickly and easily in E. coli.


BioPharm International Supplements


REFERENCES

1. Huleatt JW, Jacobs AR, Tang J, Desai P, Kopp EB, Huang Y, et al. Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity. Vaccine. 2007;25(4):763–75.

2. Anderson KV, Bokla L, Nusslein-Volhard C. Establishment of dorsal-ventral polarity in the Drosophila embryo: the induction of polarity by the Toll gene product. Cell. 1985;42(3):791–8.

3. Bettencourt R, Tanji T, Yagi Y, Ip YT. Toll and Toll-9 in Drosophila innate immune response. J Endotoxin Res. 2004;10(4):261–8.

4. Blander JM, Medzhitov R. Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature. 2006;440(7085):808–12.

5. Medzhitov R, Janeway CA, Jr. Innate immunity: impact on the adaptive immune response. Curr Opin Immunol. 1997;9(1):4–9.

6. Kawai T, Akira S. Pathogen recognition with Toll-like receptors. Clin Op Immunol. 2005;17:338–344.

7. Huleatt JW, et al. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine. 2008;26:201–214.

8. McDonald WF, Huleatt JW, Foellmer HG, Hewitt D, Tang J, Desai P, Price A, Jacobs A, Takahashi VN, Huang Y, Nakaar V, Alexopoulou L, Fikrig E, Powell TJ. A West Nile virus recombinant protein vaccine that co-activates innate and adaptive immunity. J Infect Dis. 2007;195:1607–17.

9. Zebedee SL, Lamb RA. Growth Restriction of Influenza A Virus by M2e Protein Antibody is Genetically linked to the M1 Protein. Proc Natl Acad Sci USA. 1989 Feb;86(3):1061–5.

10. Song L, Nakaar V, et al. Efficacious recombinant influenza vaccines produced by high yield bacterial expression: a solution to global pandemic and seasonal needs. PLoS ONE. 2008;3:e2257.

11. Yewdell JW, Caton AJ, Gerhard W. Selection of influenza A virus adsorptive mutants by growth in the presence of a mixture of monoclonal antihemagglutinin antibodies. J Virol. 1986;57:623–628.

12. Matthews JT. Egg-based production of influenza vaccine: 30 years of commercial experience. National Academy of Engineering. 2006;36.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Bristol-Myers Squibb and Five Prime Therapeutics Collaborate on Development of Immunomodulator
November 26, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
Author Guidelines
Source: BioPharm International Supplements,
Click here